News: Venus Remedies, a prominent pharmaceutical company, is all set to reveal its financial performance for the third quarter of 2024. Investors and stakeholders eagerly await this update to assess the company’s growth trajectory. In this article, we’ll delve into the key details you need to know about Venus Remedies’ Q3 results.
1. Date and Time of Announcement
Mark your calendars! Venus Remedies will announce its Q3 results on February 14, 2024. The company’s management team will provide insights into their performance during this period.
2. Share Price Insights
As of February 9, 2024, Venus Remedies’ share price stood at Rs. 400.65 on the National Stock Exchange (NSE). Over the past month, the share price has experienced a slight decline of 0.11%¹. Investors should closely monitor any fluctuations following the Q3 results announcement.
Subscribe to Sarkari Result to stay informed. Get the latest celebrity news and detailed movie reviews in real-time. Keep up with the constantly changing world of entertainment with Sarkari Exam.
3. Quarterly Performance Highlights
Let’s take a closer look at Venus Remedies’ Q3 performance:
a. Revenue Growth
- Venus Remedies witnessed an impressive QoQ revenue growth of 75.31%, which is the highest in the last three years. This indicates robust business activity during the quarter¹.
- However, it’s essential to note that sales experienced a contraction, declining by 6.78%. This is the first revenue contraction the company has seen in the past three years¹.
b. Cost Management
- The company allocated less than 1% of its operating revenues toward interest expenses and approximately 11.04% toward employee costs in the fiscal year ending March 31, 2023.
4. Stock Metrics
Here are some key metrics related to Venus Remedies’ stock:
- PE Ratio: 21.03
- Earnings per Share (EPS) – TTM: ₹19.05
- Market Capitalization: ₹535.55 crore
- Price-to-Book (PB) Ratio: 1.15
- Dividend Yield: 0.00%
- Face Value: ₹10.00
- Beta (1 Year): 1.37
About Venus Remedies Company
Venus Remedies is an Indian research-driven pharmaceutical company committed to advancing patient outcomes through innovative solutions. Let’s explore some key aspects of this company:
1. Company Overview
Venus Remedies Limited (VRL) is a prominent pharmaceutical manufacturing unit. Established in 1989, the company has made significant strides in the industry. Led by Pawan Chaudhary, the Chairman-cum-Managing Director, Venus Remedies aims to transcend mere existence and leave a positive impact on human health.
2. Research and Development Focus
Venus Remedies places a strong emphasis on cutting-edge research and development. Their commitment to quality, safety, and efficacy has resulted in successful products across various therapeutic areas. Notably, Venus is one of the largest manufacturers of meropenem antibiotics in India.
3. Product Portfolio
The company offers a diverse range of pharmaceutical products, catering to different medical needs. Some highlights include:
- Anti-infectives: Venus Remedies provides effective solutions to combat infections.
- Oncology: Their portfolio includes oncology drugs for cancer treatment.
- Pain Management: Addressing pain-related issues is another focus area.
- Novel Drug Delivery Systems: Innovations in drug delivery enhance patient experiences.
- Fixed-Dose Injectables: Convenient and precise dosing options.
With over 800 marketing authorizations globally, Venus Remedies consistently introduces new formulations to the market.
4. Social Responsibility and Sustainability
Venus recognizes its responsibility to operate ethically and transparently. The company has been Great Place to Work (GPTW)-certified three times in a row. They prioritize employee health, customer well-being, and environmental sustainability. By adhering to applicable laws and regulations, Venus Remedies ensures a positive impact on society and the environment.
Disclaimer: Please note that all content and tools on this website are provided for your convenience and are offered “as is” without warranties. The information provided, including any tool-generated output, is for informational purposes only and should not be considered investment advice or guarantees. Exercise caution, seek professional advice, and make independent judgments before acting on any information found on this site.
ncG1vNJzZmivp6x7tK3RpJiroZWtrq56wqikaK6Vo8K0edGepJ6cmZrAbr2SZqmeq6WhwW5%2Bj2trZpyRqbJurc2dZK2hnZp6tLTAq5xmqKKesKZ5wKebZqyRp7SmwI5vZ2lqZ20%3D